Durability of Therapeutic Response to Milnacipran Treatment for Fibromyalgia. Results of a Randomized, Double-Blind, Monotherapy 6-Month Extension Study
dc.contributor.author | Goldenberg, Don L. | en_US |
dc.contributor.author | Clauw, Daniel J. | en_US |
dc.contributor.author | Palmer, Robert H. | en_US |
dc.contributor.author | Mease, Philip J. | en_US |
dc.contributor.author | Chen, Wei | en_US |
dc.contributor.author | Gendreau, R. michael | en_US |
dc.date.accessioned | 2011-01-13T19:40:26Z | |
dc.date.available | 2011-01-13T19:40:26Z | |
dc.date.issued | 2010-02 | en_US |
dc.identifier.citation | Goldenberg, Don L.; Clauw, Daniel J.; Palmer, Robert H.; Mease, Philip; Chen, Wei; Gendreau, R. michael; (2010). "Durability of Therapeutic Response to Milnacipran Treatment for Fibromyalgia. Results of a Randomized, Double-Blind, Monotherapy 6-Month Extension Study." Pain Medicine 11(2): 180-194. <http://hdl.handle.net/2027.42/78636> | en_US |
dc.identifier.issn | 1526-2375 | en_US |
dc.identifier.issn | 1526-4637 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/78636 | |
dc.description.abstract | To evaluate the durability of improvement and long-term efficacy of milnacipran treatment in fibromyalgia, to assess efficacy in patients re-randomized from placebo to milnacipran, and to collect additional information on the tolerability and efficacy of long-term treatment with milnacipran.A total of 449 patients who successfully completed a 6-month lead-in study enrolled in this 6-month extension study (87.7% of eligible subjects). Patients initially receiving milnacipran 200 mg/day during the lead-in study were maintained at 200 mg/day (n = 209); patients initially assigned to placebo or milnacipran 100 mg/day were re-randomized (1:4) to either 100 mg/day (n = 48) or 200 mg/day (n = 192) of milnacipran for an additional 6 months of treatment. Efficacy assessments included visual analog scale pain ratings, Fibromyalgia Impact Questionnaire (FIQ) total score, and Patient Global Impression of Change (PGIC).Patients continuing on milnacipran demonstrated a sustained reduction in pain over the full 12-month period. Additional beneficial effects were also maintained, as indicated by the PGIC and FIQ. Patients initially assigned to either placebo or milnacipran 100 mg/day in the lead-in study and subsequently re-randomized to milnacipran 200 mg/day in the extension study experienced further improvements in their mean pain scores, FIQ total scores, and PGIC ratings at 1 year. Milnacipran treatment was generally well tolerated. The most commonly reported newly emergent adverse event was nausea.In addition to confirming that milnacipran safely and effectively improves the multiple symptoms of fibromyalgia, these data indicate that milnacipran provides 1-year durable efficacy in this patient population. | en_US |
dc.format.extent | 553119 bytes | |
dc.format.extent | 3106 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Inc | en_US |
dc.subject.other | Fibromyalgia | en_US |
dc.subject.other | Milnacipran | en_US |
dc.subject.other | Serotonin-Norepinephrine Reuptake Inhibitor | en_US |
dc.subject.other | Pain | en_US |
dc.subject.other | Analgesic | en_US |
dc.subject.other | Long Term | en_US |
dc.title | Durability of Therapeutic Response to Milnacipran Treatment for Fibromyalgia. Results of a Randomized, Double-Blind, Monotherapy 6-Month Extension Study | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Anesthesiology and Medicine, University of Michigan Medical School, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Department of Medicine, Newton-Wellesley Hospital, Newton, Massachusetts | en_US |
dc.contributor.affiliationother | Forest Research Institute, Jersey City, New Jersey | en_US |
dc.contributor.affiliationother | Seattle Rheumatology Associates, Seattle, Washington | en_US |
dc.contributor.affiliationother | Cypress Bioscience, Inc., San Diego, California, USA | en_US |
dc.identifier.pmid | 20002596 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/78636/1/j.1526-4637.2009.00755.x.pdf | |
dc.identifier.doi | 10.1111/j.1526-4637.2009.00755.x | en_US |
dc.identifier.source | Pain Medicine | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.